Pharmaceuticals - Canada

Canada

The Pharmaceuticals market in Canada is expected to witness a significant growth in the coming years.
By 2024, the projected revenue for this market is estimated to reach US$20.26bn.
Among the various markets, Oncology Drugs is anticipated to be the largest, with a projected market volume of US$3.90bn by 2024.
Furthermore, the Pharmaceuticals market in Canada is expected to exhibit a steady annual growth rate of 6.43% from 2024 to 2028, resulting in a market volume of US$26.00bn by 2028.
In terms of global comparison, United States is projected to generate the highest revenue in the Pharmaceuticals market, reaching US$636.90bn in 2024.
Canada's pharmaceutical market is experiencing a surge in demand for innovative biologics and personalized medicine.

Key regions: United States, China, Germany, Japan, Europe

Definition:
The Pharmaceuticals market covers remedies used to cure, treat, prevent, and diagnose diseases. These small molecule drugs or biologic medical products may be called drugs, medications, or medicines. Prescription drugs and over-the-counter (OTC) drugs are both included. Depending on the regulations in each country, these products are provided by pharmacies, hospitals, physicians, and/or drug stores, and/or they can be bought elsewhere. They may be administered in the form of pills, capsules, gels, ointments, injections, infusions, lozenges, or aerosols/sprays.

Structure:
The market is subdivided into Oncology Drugs, Anti-Diabetes Drugs, Anti-Rheumatic Drugs, Vaccines, Dermatological Drugs, Antiviral Drugs, Immunosuppressants, Bronchodilator Drugs, Sensory Organ Drugs, Anti-Hypertensive Drugs, Anti-Coagulants, Anti-Fibrinolytic Drugs, Multiple Sclerosis Drugs, Lipid-Lowering Agents and Other Pharmaceuticals. The Pharmaceuticals market is organized in markets that cover drugs used in specific medical fields, i.e., medicines for a specific disesase or a certain type of medicine. They include original brands, biosimilars, generics, and orphan drugs.The Oncology Drugs market covers pharmaceutical products specifically developed for the treatment and management of various cancers. The Anti-Diabetes Drugs market covers medications designed to manage blood glucose levels and improve insulin sensitivity in individuals with diabetes. The market Anti-Rheumatic Drugs includes pharmaceuticals specifically developed to alleviate symptoms, reduce inflammation, and modify the progression of rheumatic diseases. The Dermatological Drugs market covers pharmaceuticals formulated to treat and manage a wide range of skin conditions such as eczema, acne, and rosacea. The Antiviral Drugs market includes medications designed to treat viral infections and reducing the severity and duration of symptoms. The Immunosuppressants market covers pharmaceuticals that suppress the immune system's activity. The Bronchodilator Drugs market covers pharmaceuticals designed to relax and widen the airways in the lungs. The Sensory Organ Drugs market covers pharmaceuticals targeting the treatment of disorders and conditions affecting sensory organs such as the eyes, ears and nose. The Anti-hypertensive Drugs market covers pharmaceuticals designed to lower blood pressure levels. The Anti-Coagulants Drugs market covers pharmaceuticals developed to prevent the formation of blood clots or to dissolve existing clots. The Anti-Fibrinolytics Drugs market covers pharmaceuticals designed to inhibit the breakdown of blood clots. The Multiple Sclerosis Drugs market covers pharmaceuticals aimed at managing and modifying the course of multiple sclerosis. The Lipid-Lowering Agents market covers pharmaceuticals developed to reduce levels of cholesterol and other lipids in the blood. The Other Pharmaceuticals market provides information on additional specialties that are not covered by the main markets.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novartis, Roche, Pfizer, Merck & Co, Johnson & Johnson, AbbVie, Sanofi.

Market

Region

Region comparison

Currency

Analyst Opinion

Canada, a country known for its natural beauty and hockey, has a thriving pharmaceuticals market.

Customer preferences: Canadian customers are increasingly looking for personalized healthcare solutions. They prefer treatments that are tailored to their specific needs and lifestyles. Additionally, they are willing to pay a premium for high-quality pharmaceutical products.

Trends in the market: One of the major trends in the Canadian pharmaceuticals market is the increasing focus on research and development. Pharmaceutical companies are investing heavily in R&D to develop innovative products that can address unmet medical needs. Another trend is the growing demand for generic drugs. As the Canadian government looks for ways to reduce healthcare costs, it has encouraged the use of generic drugs as a cost-saving measure.

Local special circumstances: One of the unique aspects of the Canadian pharmaceuticals market is the role of the government. The government plays a significant role in regulating drug prices and approving new drugs for use in the country. Additionally, the country's universal healthcare system means that the government is the largest purchaser of pharmaceuticals in Canada.

Underlying macroeconomic factors: Several macroeconomic factors are driving the growth of the pharmaceuticals market in Canada. One of the most significant is the country's aging population. As the population ages, there is an increasing demand for pharmaceutical products to treat age-related illnesses. Additionally, the country's strong economy and high standard of living mean that Canadians have more disposable income to spend on healthcare. Finally, the government's commitment to universal healthcare ensures that there is a steady demand for pharmaceutical products in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.